NephRx Corporation
Pioneering treatments for kidney failure, renal disorders, and gastrointestinal diseases.
Pioneering treatments for kidney failure, renal disorders, and gastrointestinal diseases.
NephRx Corporation, established in 1995, is a biotechnology company with a focus on pioneering treatments for kidney failure, renal disorders, and gastrointestinal diseases. The company's offerings include NX001, which aids in the treatment of delayed graft function in kidney transplant patients, and NX002, a peptide derived from the natural growth factor AMP-18. Headquartered in Kalamazoo, Michigan, NephRx Corporation received a $6.22M Venture Round investment on 10 February 2010. This funding reflects confidence in the company's innovative approach to addressing critical medical needs within the Biotechnology, Health Care, and Health and Wellness industries. NephRx Corporation's pioneering efforts in developing therapeutic products position it as a key player in addressing unmet medical needs, signaling potential for impactful advancements in the treatment of acute kidney failure and gastrointestinal diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $6.22M | - | 10 Feb 2010 |
No recent news or press coverage available for NephRx Corporation.
We care about your data, and we'd love to use cookies make your experience better.
